Imeik Technology Development Co

Imeik Technology Development Co Receivables

The Accounts Receivable of Imeik Technology Development Co (300896.SZ) as of Oct 16, 2026 is 168.45 M CNY. In the previous year, Accounts Receivable was 206.07 M CNY — a change of -18.25% (lower).

Receivables

168.45 MCNY

YoY

-18.25%

Last updated:

Accounts Receivable of Imeik Technology Development Co is 2024 168.45 M CNY. Accounts Receivable of Imeik Technology Development Co was 2023 206.07 M CNY. It decreases by -18.25% lower compared to the previous year.

The Imeik Technology Development Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
4.40 M CNY
Jan 1, 2018
9.10 M CNY
Jan 1, 2019
14.70 M CNY
Jan 1, 2020
29.80 M CNY
Jan 1, 2021
72.35 M CNY
Jan 1, 2022
127.76 M CNY
Jan 1, 2023
206.07 M CNY
Jan 1, 2024
168.45 M CNY
The Imeik Technology Development Co Receivables history
YEARReceivablesYoY
168.45 MCNY-18.25%
206.07 MCNY+61.30%
127.76 MCNY+76.58%
72.35 MCNY+142.79%
29.80 MCNY+102.72%
14.70 MCNY+61.54%
9.10 MCNY+106.82%
4.40 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co Ltd is a biotechnology company based in Beijing, China, operating within the healthcare sector. The company focuses on the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. It has established a product technology transformation platform for biomedical materials, including medical chitosan and polylactic acid. Imeik has successfully industrialized injection-type sodium hyaluronate series products and polydioxanone facial implants. Its self-developed products are primarily designed for the repair of facial and neck skin folds, with clinical applications spanning medical cosmetology, surgical repair, and the treatment of metabolic diseases. The company went public on the Shenzhen Stock Exchange on September 28, 2020, with ticker 300896.SZ and ISIN CNE100004868. Imeik currently employs 713 full-time staff and operates exclusively within the Chinese market. Its website is www.imeik.net, providing information on its products and services. The company emphasizes the development and transformation of biomedical materials, aiming to advance biomedicine through its specialized focus on recombinant proteins and peptides. It has developed a range of products that address specific medical and cosmetic needs, contributing to its position in the healthcare industry. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Accounts Receivable of Imeik Technology Development Co is 168.45 M CNY in 2024.

Accounts Receivable of Imeik Technology Development Co changed from 206.07 M CNY to 168.45 M CNY, representing a -18.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Imeik Technology Development Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Imeik Technology Development Co

All Key Metrics — Imeik Technology Development Co